Apimeds Pharmaceuticals US, Inc
APUSAMEX
Healthcare
Drug Manufacturers - Specialty & Generic
$1.88
+0.13(7.4%)
52W $1.10 – $3.90
Quick:
8-K
Mar 26, 2026 (1 weeks ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Mar 25, 2026 (1 weeks ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K/A
Feb 17, 2026 (1 months ago)Current Report (Amendment)
Material event disclosure
Event materiality and market reaction
SCHEDULE 13G
Feb 11, 2026 (1 months ago)Beneficial Ownership
Large shareholder position disclosure
Ownership threshold, passive vs active
SCHEDULE 13D/A
Jan 26, 2026 (2 months ago)SCHEDULE 13D/A (Amendment)
SEC filing disclosure
Filing details and context
8-K
Jan 2, 2026 (3 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Dec 10, 2025 (3 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K/A
Dec 10, 2025 (3 months ago)Current Report (Amendment)
Material event disclosure
Event materiality and market reaction
8-K
Dec 2, 2025 (4 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Nov 18, 2025 (4 months ago)Current Report
Material event disclosure
Event materiality and market reaction
10-Q
Nov 12, 2025 (4 months ago)Quarterly Report
Quarterly financial update
Sequential growth, guidance changes
8-K
Oct 16, 2025 (5 months ago)Current Report
Material event disclosure
Event materiality and market reaction
10-Q
Aug 19, 2025 (7 months ago)Quarterly Report
Quarterly financial update
Sequential growth, guidance changes
8-K
Jul 16, 2025 (8 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Jun 5, 2025 (10 months ago)Current Report
Material event disclosure
Event materiality and market reaction
10-Q
May 20, 2025 (10 months ago)Quarterly Report
Quarterly financial update
Sequential growth, guidance changes
8-K
May 12, 2025 (10 months ago)Current Report
Material event disclosure
Event materiality and market reaction
10-K/A
May 2, 2025 (11 months ago)Annual Report (Amendment)
Full-year financial statements and risk factors
YoY revenue/margin trends, new risk disclosures
8-K
Apr 15, 2025 (11 months ago)Current Report
Material event disclosure
Event materiality and market reaction
10-K
Apr 15, 2025 (11 months ago)Annual Report
Full-year financial statements and risk factors
YoY revenue/margin trends, new risk disclosures